At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 432 enrolled
Drug / intervention
cemiplimabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating cemiplimab for Advanced Cutaneous Squamous Cell Carcinoma. Completed, enrolled 432 participants across 78 sites in 8 countries.
Detailed Summary
The goals of this study are to evaluate the clinical benefit and safety of cemiplimab in participants with metastatic (nodal or distant) Cutaneous Squamous Cell Carcinoma (CSCC), or unresectable locally advanced CSCC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Brazil, France, Germany, Greece, Italy, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2016
First PostedMay 2016
Primary CompletionOct 2023
TodayJul 2026
First PostedMay 3, 2016
Enrollment StartApr 7, 2016
Primary CompletionOct 18, 2023
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 10.2 years ago
Interventions
cemiplimabdrug